Top

Mindfulness

Gepubliceerd in:

11-10-2021 | ORIGINAL PAPER

Testing Mindfulness-Based Relapse Prevention with Medications for Opioid Use Disorder Among Adults in Outpatient Therapy: a Quasi-experimental Study

Auteurs: Keith J. Zullig, Laura R. Lander, Meghan Tuscano, Megan Garland, Gerry R. Hobbs, Laurel Faulkenberry

Gepubliceerd in: Mindfulness | Uitgave 12/2021

Abstract

Objectives

This study aimed to explore the effectiveness of mindfulness-based relapse prevention (MBRP) with individuals receiving medication for opioid use disorder (MOUD) in a naturalistic, open-ended outpatient group treatment setting.

Methods

Eighty participants (mean age 36.3) who had at least 90 consecutive days substance free self-selected into treatment (MBRP, n = 35) or comparison groups (treatment as usual, TAU, n = 45). Outcomes tracked included treatment retention and relapse, and self-reported craving, anxiety, depression, and mindfulness at baseline, 12 weeks, 24 weeks, and 36 weeks post-recruitment. MBRP group participants attended biweekly 60-min sessions for 24 weeks. A linear mixed model analysis of variance determined the significance of the MBRP intervention on changes in craving, anxiety, depression, and mindfulness.

Results

No significant differences in sex, education level, insurance status, relationship status, or employment status were detected at baseline between groups. The 36-week retention (74%, MBRP/MOUD; 71%, TAU/MOUD) and relapse rates (43%, MBRP/MOUD; 47%, TAU/MOUD) were similar for the groups. There were only four relapses on opioids. Significant reductions (p < .05) were observed in the MBRP/MOUD group for craving, anxiety, and depression in addition to significant increases in mindfulness compared to those in TAU/MOUD.

Conclusions

Although state and federal resources are available to expand MOUD, no standard of behavioral therapy has been established as most complimentary to MOUD. The current study results suggest MBRP can be implemented as an outpatient therapy for individuals in MOUD.

vorige artikel EEG Characteristics During Mindfulness Meditation Among Buddhist Monks in a Sri Lankan Forest Monastery

volgende artikel Enhancing Cognition in Older Persons with Depression or Anxiety with a Combination of Mindfulness-Based Stress Reduction (MBSR) and Transcranial Direct Current Stimulation (tDCS): Results of a Pilot Randomized Clinical Trial

Ahmad, F. B., Rossen, L. M. & Sutton, P. (2021). Provisional drug overdose death counts. National Center for Health Statistics, US Center for Disease Control and Prevention. Retrieved June 25, 2021 from https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.

Andrilla, C. H. A., Moore, T. E., Patterson, D. G., & Larson, E. H. (2019). Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. The Journal of Rural Health, 35(1), 108–112. https://doi.org/10.1111/jrh.12307CrossRefPubMed

Baer, R. A., Smith, G. T., Hopkins, J., Krietemeyer, J., & Toney, L. (2006). Using self-report assessment methods to explore facets of mindfulness. Assessment, 13(1), 27–45. https://doi.org/10.1177/1073191105283504CrossRefPubMed

Bentley, K. H., Gallagher, M. W., Carl, J. R., & Barlow, D. H. (2014). Development and validation of the Overall Depression Severity and Impairment Scale. Psychological Assessment, 26(3), 815–830. https://doi.org/10.1037/a0036216CrossRefPubMed

Bowen, S., Somohano, V. C., Rutkie, R. E., Manuel, J. A., & Rehder, K. L. (2017). Mindfulness-based relapse prevention for methadone maintenance: A feasibility trial. JOurnal of Alternative and Complementary Medicine, 23(7), 541–544. https://doi.org/10.1089/acm.2016.0417CrossRefPubMed

Bowen, S., Witkiewitz, K., Dillworth, T. M., Chawla, N., Simpson, T. L., Ostafin, B., Larimer, M. E., Blume, A. W., Parks, G. A., & Marlatt, G. A. (2006). Mindfulness meditation and substance use in an incarcerated population. Psychology of Addictive Behaviors, 20(3), 343–347. https://doi.org/10.1037/0893-164X.20.3.343CrossRefPubMed

Bowen, S., Witkiewitz, K., Clifasefi, S. L., Grow, G., Chawla, N., Hsu, S. H., Carroll, H. A., Harrop, E., Collins, S. E., Lustyk, M. K., & Larimer, M. E. (2014). Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders: A randomized clinical trial. JAMA Psychiatry, 71(5), 547–556. https://doi.org/10.1001/jamapsychiatry.2013.4546CrossRefPubMedPubMedCentral

Carroll, K., & Weiss, R. (2017). The role of behavioral treatments in buprenorphine maintenance treatment: A review. American Journal of Psychiatry, 174(8), 738–747. https://doi.org/10.1176/appi.ajp.2016.16070792CrossRef

Campbell-Sills, L., Norman, S. B., Craske, M. G., Sullivan, G., Lang, A. J., Chavira, D. A., Bystritsky, A., Sherbourne, C., Roy-Byrne, P., & Stein, M. B. (2009). Validation of a brief measure of anxiety-related severity and impairment: The Overall Anxiety Severity and Impairment Scale (OASIS). Journal of Affective Disorders, 112(1–3), 92–101. https://doi.org/10.1016/j.jad.2008.03.014CrossRefPubMed

Centers for Disease Control and Prevention (CDC, 2017). Opioid overdose: Drug overdose death data. Retrieved March 4, 2021 from https://www.cdc.gov/drugoverdose/data/statedeaths.html

Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Multiple Cause of Death 1999–2014 on CDC WONDER Online Database. (2015). Data are from the Multiple Cause of Death Files, 1999–2014, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Retrieved March 4, 2021from http://wonder.cdc.gov/mcd-icd10.html

Franken, I. H. A., Hendriks, V. M., & van den Brink, W. (2002). Initial validation of two opiate craving questionnaires: The Obsessive Compulsive Drug Use Scale and the Desires for Drug Questionnaire. Addictive Behaviors, 27(5), 675–685. https://doi.org/10.1016/s0306-4603(01)00201-5CrossRefPubMed

Garland, E. L. (2013). A mindfulness oriented recovery enhancement for addiction, stress, and pain. NASW Press.

Garland, E. L., Froeliger, B., Zeidan, F., Partin, K., & Howard, M. O. (2013). The downward spiral of chronic pain, prescription opioid misuse, and addiction: Cognitive, affective, and neuropsychopharmacologic pathways. Neuroscience & Biobehavioral Reviews, 37(10), 2597–2607. https://doi.org/10.1016/j.neubiorev.2013.08.006CrossRef

Garland, E. L., Gaylord, S. A., Boettiger, C. A., & Howard, M. O. (2010). Mindfulness training modifies cognitive, affective, and physiological mechanisms implicated in alcohol dependence: Results of a randomized controlled trial. Journal of Psychoactive Drugs, 42(2), 177–192. https://doi.org/10.1080/02791072.2010.10400690CrossRefPubMedPubMedCentral

Grant, S., Hempel, S., Colaiaco, B., Motala, A., & SHanman, R.M., Booth, M., Dudley, W., Sorbero, M.E. . (2015). Mindfulness-based relapse prevention for substance use disorder: A systematic review. Rand Corporation.

Gu, J., Strauss, C., Bond, R., & Cavanagh, K. (2015). How do mindfulness-based cognitive therapy and mindfulness-based stress reduction improve mental health and wellbeing? A systematic review and meta-analysis of mediation studies. Clinical Psychological Review, 37, 1–12.CrossRef

Hedegaard, H., Miniño, A.M., & Warner, M. (2020). Drug overdose deaths in the United States, 1999–2018. NCHS Data Brief, no 356. Hyattsville, MD: National Center for Health Statistics. Retrieved March 4, 2021 from https://stacks.cdc.gov/view/cdc/84647

Ivtzan, I. (2020). Handbook of mindfulness-based programmes. Routledge.

Korecki, R.J., Schwebel, F.J., Votaw, V.R., & Witkiewitz, K. (2020). Mindfulness-based programs for substance use disorders: A systematic review of manualized treatments. Substance Abuse Treatment, Prevention, and Policy. https://doi.org/10.1186/s13011-020-00293-3

Larochelle, M., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137–145. https://doi.org/10.7326/M17-3107CrossRefPubMedPubMedCentral

Norman, S. B., Cissell, S. H., Means-Christensen, A. J., & Stein, M. B. (2006). Development and validation of an Overall Anxiety Severity and Impairment Scale (OASIS). Depression and Anxiety, 23(4), 245–249. https://doi.org/10.1002/da.20182CrossRefPubMed

Penberthy, J. K., Konig, A., Gioia, C. J., Rodríguez, V. M., Starr, J. A., Meese, W., Worthington-Stoneman, D., Kersting, K., & Natanya, E. (2015). Mindfulness-based relapse prevention: History, mechanisms of action, and effects. Mindfulness, 6(2), 151–158. https://doi.org/10.1007/s12671-013-0239-1CrossRef

Roos, C., Kirouac, M., Stein, E., Wilson, A., Bowen, S., & Witkiewitz, K. (2019). An open trial of rolling admission mindfulness-based relapse prevention (Rolling MBRP): Feasibility, acceptability, dose-response relations, and mechanisms. Mindfulness, 10(6), 1062–1073. https://doi.org/10.1007/s12671-018-1054-5CrossRefPubMed

Roos, C. R., Bowen, S., & Witkiewitz, K. (2017). Baseline patterns of substance use disorder severity and depression and anxiety symptoms moderate the efficacy of mindfulness-based relapse prevention. Journal of Consulting and Clinical Psychology, 85, 1041–1051. https://doi.org/10.1037/ccp0000249CrossRefPubMedPubMedCentral

Sobell, L. C., & Sobell, M. B. (1996). Timeline Follow Back user’s guide: A calendar method for assessing alcohol and drug use. Toronto, Canada: Addiction Research Foundation.

Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. British Medical Journal, 357, j1550. https://doi.org/10.1136/bmj.j1550CrossRefPubMedPubMedCentral

Substance Abuse and Mental Health Services Administration (SAMHSA, 2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20–07–01–001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.

Tolliver, B., & Anton, R. (2015). Assessment and treatment of mood disorders in the context of substance abuse. Dialogues in clinical neuroscience, 17(2), 181–190. https://doi.org/10.31887/DCNS.2015.17.2CrossRefPubMedPubMedCentral

Timko, C., Schultz, N. R., Cucciare, M. A., Vittorio, L., & Garrison-Diehn, C. (2016). Retention in medication-assisted treatment for opiate dependence: A systematic review. Journal of Addictive Diseases, 35(1), 22–35. https://doi.org/10.1080/10550887.2016.1100960CrossRefPubMed

U.S. Congress. (2015). Recovery Enhancement for Addiction Treatment Act. Retrieved March 24, 2021 from http://www.markey.senate.gov/imo/media/doc/2015-05-27-TREAT-Act-BillText.pdf.

Winstanley, E. L., Lander, L. R., Berry, J. H., Mahoney, J. J., Zheng, W., Herschler, J., Marshalek, P., Sayres, S., Mason, J., & Haut, M. W. (2020). West Virginia’s model of buprenorphine expansion: Preliminary results. Journal of Substance Abuse Treatment, 108, 40–47. https://doi.org/10.1016/j.jsat.2019.05.005CrossRefPubMed

Witkiewitz, K., Warner, K., Sully, B., Barricks, A., Stauffer, C., Thompson, B. L., & Luoma, J. B. (2014). Randomized trial comparing mindfulness-based relapse prevention with relapse prevention for women offenders at a residential addiction treatment center. Substance Use & Misuse, 49(5), 536–546. https://doi.org/10.3109/10826084.2013.856922CrossRef

Witkiewitz, K., Bowen, S., Douglas, H., & Hsu, S. H. (2013). Mindfulness-based relapse prevention for substance craving. Addictive Behaviors, 38(2), 1563–1571. https://doi.org/10.1016/j.addbeh.2012.04.001CrossRefPubMed

Zullig, K. J., Lander, L. R., Sloan, S., Brumage, M. R., Hobbs, G. R., & Faulkenberry, L. (2018). Mindfulness-based relapse prevention with individuals receiving medication-assisted outpatient treatment for opioid use disorder. Mindfulness, 9, 423–429. https://doi.org/10.1007/s12671-017-0784-0CrossRef

Zheng, W., Nickasch, M., Lander, L., Wen, S., Xiao, M., Marshalek, P., Dix, E., & Sullivan, C. (2017). Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: A 2-year retrospective data analysis. Journal of Addiction Medicine, 11(2), 138–144. https://doi.org/10.1097/ADM.0000000000000287CrossRefPubMedPubMedCentral

Titel: Testing Mindfulness-Based Relapse Prevention with Medications for Opioid Use Disorder Among Adults in Outpatient Therapy: a Quasi-experimental Study
Auteurs: Keith J. Zullig
Laura R. Lander
Meghan Tuscano
Megan Garland
Gerry R. Hobbs
Laurel Faulkenberry
Publicatiedatum: 11-10-2021
Uitgeverij: Springer US
Gepubliceerd in: Mindfulness / Uitgave 12/2021
Print ISSN: 1868-8527
Elektronisch ISSN: 1868-8535
DOI: https://doi.org/10.1007/s12671-021-01763-w

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Objectives

Methods

Results

Conclusions

Log in om toegang te krijgen

Andere artikelen Uitgave 12/2021

Puncture your Papañca

Metta-Based Therapy for Chronic Depression: a Wait List Control Trial

The Mediating Role of Dispositional Mindfulness in the Associations Between Intimate Violence, Self-esteem, and Distress Among Adolescents

The Efficacy of a Mindfulness-Based Intervention for College Students Under Extremely Stressful Conditions

Family Mindfulness Training for Childhood ADHD: Short- and Long-Term Effects on Children, Fathers and Mothers

Mindfulness in Relation to Diet Quality in Adults with Type 1 and Type 2 Diabetes: Results from Diabetes MILES-The Netherlands